TrialBlood cancer journal2022

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.

Sangeetha Venugopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.